BioLineRx to Report Fourth Quarter and Year End 2012 Results on March 12, 2013

  BioLineRx to Report Fourth Quarter and Year End 2012 Results on March 12,
  2013

           – Management to hold conference call at 10:00 a.m. EST–

Business Wire

JERUSALEM -- February 26, 2013

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development
company, announced today that it will release its financial results for the
quarter and year ended December 31, 2012 on Tuesday, March 12, 2013, before
the U.S. markets open.

The Company will host a conference call on Tuesday, March 12 at 10:00 a.m. EST
featuring remarks by Kinneret Savitsky, Ph.D., CEO of BioLineRx, and Philip
Serlin, Chief Financial and Operating Officer of BioLineRx. The conference
call will be available via webcast and can be accessed through the Investor
Relations section of BioLineRx’s website, www.biolinerx.com, and www.kcsa.com.
Please allow extra time prior to the call to visit the site and download any
necessary software to listen to the live broadcast. To dial into the
conference call, please dial 1-888-407-2553 from the U.S. or +972-3-918-0610
internationally.

A replay of the conference call will be available approximately two hours
after completion of the live conference call at www.biolinerx.com or
www.kcsa.com.A dial-in replay of the call will be available until March 15,
2013; please dial 1-877-456-0009 from the U.S. or +972-3-925-5927
internationally.

About BioLineRx

BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet medical
needs or with advantages over currently available therapies. BioLineRx’s
current portfolio consists of six clinical stage candidates: BL-1020 for
schizophrenia is currently undergoing a Phase II/III study; BL-1040, for
prevention of pathological cardiac remodeling following a myocardial
infarction, which has been out-licensed to Ikaria Inc., is currently
undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical
removal of skin lesions has completed a Phase I/II study; BL-1021 for
neuropathic pain is in Phase I development, BL-7040 for treating inflammatory
bowel disease (IBD) is currently undergoing a Phase II trial, and BL-8040 for
treating acute myeloid leukemia (AML) and other hematological cancers has
completed Phase I. In addition, BioLineRx has eight products in various
pre-clinical development stages for a variety of indications, including
central nervous system diseases, infectious diseases, cardiovascular and
autoimmune diseases.

BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company performs
feasibility assessment studies and development through pre-clinical and
clinical stages, with partial funding from the Israeli Government’s Office of
the Chief Scientist (OCS). The final stage includes partnering with medium and
large pharmaceutical companies for advanced clinical development (Phase III)
and commercialization. For more information on BioLineRx, please visit
www.biolinerx.com, the content of which does not form a part of this press
release.

Various statements in this release concerning BioLineRx’s future expectations,
including specifically those related to the development and commercialization
of BL-1020, constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements include
words such as “may,” “expects,” “anticipates,” “believes,” and “intends,” and
describe opinions about future events. These forward-looking statements
involve known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of BioLineRx to be materially different
from any future results, performance or achievements expressed or implied by
such forward-looking statements. Some of these risks are: changes in
relationships with collaborators; the impact of competitive products and
technological changes; risks relating to the development of new products; and
the ability to implement technological improvements. These and other factors
are more fully discussed in the “Risk Factors” section of BioLineRx’s most
recent annual report on Form 20-F filed with the Securities and Exchange
Commission on March 22, 2012. In addition, any forward-looking statements
represent BioLineRx’s views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date. BioLineRx
does not assume any obligation to update any forward-looking statements unless
required by law.

Contact:

KCSA Strategic Communications
Garth Russell / Todd Fromer
1 212-896-1250 / 1 212-896-1215
grussell@kcsa.com/tfromer@kcsa.com
or
BioLineRx Ltd.
Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipih@netvision.net.il